Biotech consulting, investing by NIH scientists curbed
Article Abstract:
Elias Zerhouni, the director of National Institutes of Health (NIH), stated in February 2005 that he would halt consulting arrangements by NIH scientists and severely restrict investments by them in biotechnology and other companies developing and making therapeutic and diagnostic products. Observers state that the new policy would constrict the flow of valuable technical knowledge from NIH to the private sector.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
The business of developing antibacterials
Article Abstract:
Research continues into development of new antibacterial drugs as demand for them is increasing day by day. Although some technical approaches have fallen short in the antibacterial drug discovery, many small biotech companies and a few major pharma companies are seeking new products for this medically important modest-growth market.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Lester Crawford
Article Abstract:
Veterinarian Lester Crawford, is nominated to be the Commissioner of the US Food and Drug Administration (FDA). Crawford, before his FDA postings, served as administrator of the Food Safety and Inspection Service at the US Department of Agriculture and did stints consulting for the World Health Organization.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
User Contributions:
Comment about this article or add new information about this topic: